BTIG Reiterates Buy on Stoke Therapeutics, Maintains $39 Price Target

BTIG analyst Thomas Shrader has reiterated a Buy rating on Stoke Therapeutics (NASDAQ: STOK) and has maintained a price target of $39 for the stock. This endorsement reflects confidence in the company's performance and potential in the market.